Abstract
Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Current Alzheimer Research
Title:Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Volume: 13 Issue: 4
Author(s): Dario Tejera and Michael T. Heneka
Affiliation:
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Abstract: Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Export Options
About this article
Cite this article as:
Tejera Dario and Heneka T. Michael, Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116125012
DOI https://dx.doi.org/10.2174/1567205013666151116125012 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets